News articles about Ra Pharmaceuticals (NASDAQ:RARX) have trended somewhat positive on Sunday, according to Accern Sentiment. The research group rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Ra Pharmaceuticals earned a coverage optimism score of 0.21 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.0460663047745 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of Ra Pharmaceuticals (RARX) traded up $0.19 during mid-day trading on Friday, hitting $8.28. The stock had a trading volume of 145,666 shares, compared to its average volume of 310,793. Ra Pharmaceuticals has a 12-month low of $7.15 and a 12-month high of $27.84. The firm has a market capitalization of $191.75 and a price-to-earnings ratio of -3.35.

Ra Pharmaceuticals (NASDAQ:RARX) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.68) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.06). sell-side analysts forecast that Ra Pharmaceuticals will post -2.46 earnings per share for the current fiscal year.

A number of brokerages have recently commented on RARX. Zacks Investment Research raised Ra Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, September 5th. Credit Suisse Group lifted their price target on Ra Pharmaceuticals from $19.00 to $23.00 and gave the company an “outperform” rating in a research note on Friday, November 10th. Royal Bank of Canada began coverage on Ra Pharmaceuticals in a research note on Thursday, September 14th. They set an “outperform” rating and a $21.00 price target on the stock. BMO Capital Markets lifted their price target on Ra Pharmaceuticals in a research note on Tuesday, December 5th. Finally, Jefferies Group reissued a “buy” rating and set a $25.00 price target on shares of Ra Pharmaceuticals in a research note on Thursday, September 28th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $23.20.

ILLEGAL ACTIVITY NOTICE: “Ra Pharmaceuticals (RARX) Receiving Somewhat Positive News Coverage, Study Finds” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://theolympiareport.com/2017/12/24/ra-pharmaceuticals-rarx-receiving-somewhat-positive-news-coverage-study-finds.html.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Insider Buying and Selling by Quarter for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.